Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046454 | 0.90 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1TRIM24TYRTRIM33 | |
| SCHEMBL11582778 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1TRIM24TYRTRIM33 | |
| SCHEMBL3046946 | 0.82 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1CNR1CNR2POLB | |
| SCHEMBL3043965 | 0.82 | PSEN1 (0.39) | ALDH1A1L3MBTL1CNR2 | |
| SCHEMBL3043051 | 0.82 | ALDH1A3 (0.40) | ALDH1A1L3MBTL1ERN1CNR1CNR2 | |
| SCHEMBL2395691 | 0.82 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1TRIM24TYRTRIM33 | |
| SCHEMBL3044441 | 0.79 | CSNK1D (0.39) | ALDH1A1L3MBTL1POLBOPRM1 | |
| SCHEMBL3043759 | 0.79 | SRC (0.38) | ALDH1A1L3MBTL1CNR1CNR2SLC6A2 | |
| SCHEMBL3041869 | 0.78 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1CNR1CNR2POLB | |
| SCHEMBL3539336 | 0.75 | NPC1 (0.34) | ALDH1A1L3MBTL1CYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | ALDH1A1 4452/4885L3MBTL1 179/4885TRIM24 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.